Published on Oct 08, 2021
2DG Medicine Price in India : Dr Reddy's Lab will come out with the pricing and roll-out of anti-covid drug 2-DG in a few days. 2-Deoxy-d-glucose is a glucose molecule which has the 2-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis.
As per the sources, the DRDO 2DG medicine price can range from 500-600 INR. It will be in the budget of people and government may come across some subsidy of that too.
2-Deoxyglucose
2-Deoxy-d-mannose
2-Deoxy-d-arabino-hexose
2-DG
Dr Sudhir Chandna was asked about the DRDO Covid Drug Price and he said that the price will depend on the production and production details are available at Dr. Reddy’s Laboratories. Dr. Reddy’s Lab are the industry partner of DRDO in the development of 2DG drug.
As per the sources, the DRDO 2DG medicine price can range from 500-600 INR. It will be in the budget of people and government may come across some subsidy of that too.
The Drugs Controller General of India (DCGI) has given permission for the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 cases, said Defence Research and Development Organisation on Saturday.
When being asked about the side effects of DRDO Anti Covid Drug, Dr. Sudhir Chandana said that the trials were done on all stages of corona patients including moderate and serious patients. All the patients got only the benefits and no side effects were noticed. So we can say that DRDO 2-DC does not have any side effects.
This drug comes in the form of powder in a sachet which is dissolved in water. This virus accumulates in infected cells and inhibits the growth of the virus by inhibiting viral synthesis and energy production. Its selective accumulation in virus-infected cells makes this drug unmatched. A large number of patients are currently experiencing severe oxygen dependence in the second Kovid-19 wave and they need to be hospitalized. This drug is expected to save valuable lives due to the way the drug is administered in infected cells. This also reduces the number of days spent in the hospital for Kovid-19 patients.
It has been reported that reports of corona patients taking this medicine have come negative in RT-PCR test. In this epidemic, this medicine can prove to be very beneficial for those battling the corona virus. The DRDO took the step of making Corona's drug-2-DG, following PM Modi's stand on being prepared against the Corona epidemic.
In April 2020, during the first wave of the epidemic, INMAS-DRDO scientists conducted experiments in the laboratory with the help of Hyderabad's Center for Cellular and Molecular Biology (CCMB) and found that this molecule was effectively against SARS-CoV-2 virus. Works and inhibits the growth of viruses. On the basis of these results, DCGI approved the second phase trial of this drug in May 2020.
DCGI allowed phase-3 clinical trials in November 2020, based on successful results. Phase-3 clinical trials were conducted on 220 patients between December 2020 to March 2021 in 27 Kovid hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. Detailed data of Phase III clinical trials were presented to DCGI. In the case of 2-DG, a significantly higher proportion of patients' symptoms were seen and by the third day patients were relieved of supplemental oxygen dependence (42 per cent, 31 per cent) as compared to SOC indicating early relief from oxygen therapy / dependence .
A similar trend was seen in patients older than 65 years. On May 1, 2021, DCGI allowed emergency use of this drug as adjuvant therapy in severe Kovid-19 patients. Being a common molecule and analog of glucose, it can be easily produced and made available in large quantities in the country.
DRDO together with its industry partner Dr. Reddy's Laboratories (DRL, Hyderabad) commenced trial testing of the safety and efficacy of the drug in COVID-19 patients. In Phase-II trials conducted during May to October 2020, the drug was found to be safe in COVID-19 patients, and there was a significant improvement in their recovery.
Phase 2A was conducted in 6 hospitals and Phase 2B (by dose) ks clinical trials were conducted in 11 hospitals across the country. Phase-II was tested on 110 patients. Among the efficacy trends, patients who were treated with 2-DG. Those patients saw rapid improvement compared to standard care (SoC) at various points.
